183 related articles for article (PubMed ID: 32658025)
1. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.
Crespo M; Zárraga S; Alonso Á; Beneyto I; Díaz Corte C; Fernandez Rodriguez AM; Franco A; Hernández D; González-Roncero FM; Jiménez Martín C; Jimeno L; Lauzurica Valdemoros LR; Llorente S; Mazuecos A; Osuna A; Ramos JP; Rodríguez Benot A; Ruiz San Millán JC; Sánchez Fructuoso A; Torregrosa JV; Guirado L;
Transplantation; 2020 Aug; 104(8 Suppl 2):S1-S12. PubMed ID: 32658025
[No Abstract] [Full Text] [Related]
2. Monitoring alloimmune response in kidney transplantation.
Bestard O; Cravedi P
J Nephrol; 2017 Apr; 30(2):187-200. PubMed ID: 27245689
[TBL] [Abstract][Full Text] [Related]
3. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
[TBL] [Abstract][Full Text] [Related]
4. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
[TBL] [Abstract][Full Text] [Related]
5. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
[TBL] [Abstract][Full Text] [Related]
10. Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.
Dorling A; Rebollo-Mesa I; Hilton R; Peacock JL; Vaughan R; Gardner L; Danzi G; Baker R; Clark B; Thuraisingham RC; Buckland M; Picton M; Martin S; Borrows R; Briggs D; Horne R; McCrone P; Kelly J; Murphy C
Trials; 2014 Jan; 15():30. PubMed ID: 24447519
[TBL] [Abstract][Full Text] [Related]
11. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
12. Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation.
Rebellato LM; Parker K; Everly MJ; Briley KP; Kendrick W; Kendrick S; Haisch CE; Terasaki PI; Bolin P
Clin Transpl; 2014; ():137-42. PubMed ID: 26281138
[TBL] [Abstract][Full Text] [Related]
13. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
[TBL] [Abstract][Full Text] [Related]
14. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
15. Beyond Criteria and Definitions: Outcome of a Standardized Antibody-Mediated Rejection Protocol with a Diagnostic Schema Different from the Banff 2009 Criteria.
Rendulic T; Ramon DS; Killen PD; Samaniego-Picota M; Park JM
Clin Transpl; 2014; ():179-87. PubMed ID: 26281143
[TBL] [Abstract][Full Text] [Related]
16. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
Peng ZG; Tian J
Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
[TBL] [Abstract][Full Text] [Related]
17. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
18. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
19. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]